missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ GSK 329

missing translation for 'orderingAttributeHoverText'
Quantity:
10 mg
missing translation for 'unitSize'
10mg
Description
GSK 329 is a potent and selective TNNI3K (cardiac troponin I-interacting kinase) inhibitor (IC50 = 10 nM). It exhibits selectivity for TNNI3K over human VEGFR2 (40-fold), p38α (80-fold), B-Raf (>200-fold) and displays >100-fold selectivity over 80% of 185 kinases tested. In vivo, GSK 329 reduces infarct size, ROS levels, and p38 activation in a mouse model of ischemia/reperfusion cardiac injury. This compound is orally bioavailable.
Spécification
Spécification
| Chemical Name or Material | N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea |
| CAS | 1268490-12-5 |
| Quantity | 10 mg |
| Target | MAPK Inhibitors |
| Molecular Formula | C19H14Cl2F3N5O2 |
| Purity | 0.98 |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu